vivani leverages proprietary technologies to develop and commercialize drug and device implants, including its lead asset npm-119 (exenatide implant), which seeks to treat patients with chronic diseases with high unmet medical need.
Company profile
Ticker
VANI
Exchange
Website
CEO
Matthew J. Pfeffer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
SECOND SIGHT MEDICAL PRODUCTS INC, SECOUND SIGHT MEDICAL PRODUCTS INC
SEC CIK
Corporate docs
Subsidiaries
Cortigent, Inc. • Nano Precision Medical, Inc. • Vivani Medical Australia Pty Ltd ...
VANI stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
22 Apr 24
S-3
Shelf registration
22 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
8-K
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
6 Mar 24
8-K
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
5 Mar 24
424B5
Prospectus supplement for primary offering
5 Mar 24
8-K
Regulation FD Disclosure
28 Feb 24
8-K
Other Events
10 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Dec 23
Transcripts
VANI
Earnings call transcript
2019 Q4
19 Mar 20
VANI
Earnings call transcript
2019 Q3
14 Nov 19
VANI
Earnings call transcript
2019 Q2
6 Aug 19
VANI
Earnings call transcript
2019 Q1
15 May 19
VANI
Earnings call transcript
2018 Q4
13 Mar 19
VANI
Earnings call transcript
2018 Q3
7 Nov 18
VANI
Earnings call transcript
2018 Q2
7 Aug 18
VANI
Earnings call transcript
2018 Q1
10 May 18
VANI
Earnings call transcript
2017 Q4
7 Mar 18
VANI
Earnings call transcript
2017 Q3
6 Nov 17
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.82 mm | 24.82 mm | 24.82 mm | 24.82 mm | 24.82 mm | 24.82 mm |
Cash burn (monthly) | 2.56 mm | 2.24 mm | 2.38 mm | 2.38 mm | 2.57 mm | 2.12 mm |
Cash used (since last report) | 17.36 mm | 15.21 mm | 16.18 mm | 16.16 mm | 17.45 mm | 14.40 mm |
Cash remaining | 7.46 mm | 9.61 mm | 8.64 mm | 8.66 mm | 7.37 mm | 10.43 mm |
Runway (months of cash) | 2.9 | 4.3 | 3.6 | 3.6 | 2.9 | 4.9 |
Institutional ownership, Q2 2023
41.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 8 |
Closed positions | 5 |
Increased positions | 6 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 3.65 bn |
Total shares | 22.73 mm |
Total puts | 498.00 |
Total calls | 10.79 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Williams Gregg | 19.36 mm | $22.46 mm |
Tanager Wealth Management | 1.65 mm | $2.00 bn |
Vanguard | 411.96 k | $498.47 mm |
Commonwealth Equity Services | 360.53 k | $436.00 k |
BLK Blackrock | 214.40 k | $259.42 mm |
Geode Capital Management | 142.55 k | $172.49 mm |
Glassman Wealth Services | 140.39 k | $169.87 mm |
Evoke Wealth | 134.87 k | $163.19 mm |
Millennium Management | 99.28 k | $120.13 mm |
CIBC Asset Management | 46.59 k | $56.38 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Bradbury Daniel | NQSO Common Stock | Grant | Acquire A | No | No | 1.43 | 26,145 | 37.39 k | 26,145 |
25 Mar 24 | Bradbury Daniel | NQSO Common Stock | Grant | Acquire A | No | No | 1.92 | 22,869 | 43.91 k | 22,869 |
15 Feb 24 | Williams Gregg | Common Stock | Buy | Acquire P | No | No | 1.01 | 1,078 | 1.09 k | 727,608 |
9 Feb 24 | Williams Gregg | Common Stock | Buy | Acquire P | No | No | 1.01 | 1,071 | 1.08 k | 726,530 |
8 Feb 24 | Williams Gregg | Common Stock | Buy | Acquire P | No | No | 1.01 | 1,119 | 1.13 k | 725,459 |
News
Vivani Medical Q4 EPS $(0.12) Beats $(0.14) Estimate
26 Mar 24
From Benzinga's Healthcare Summit: Vivani Medical Co-Founder & CEO, Adam Mendelsohn Says Co Is Not In Clinicals Yet, But Hopes To Be There Soon
20 Mar 24
From Benzinga's Healthcare Summit: Vivani Medical Co-Founder & CEO, Adam Mendelsohn Says 'If You Stop Taking Weight loss Medications Your Weight Will Come Back Fairly Quickly Co is Working On A Drug Where This Does Not Happen'
20 Mar 24
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
4 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
4 Mar 24
Press releases
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
6 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
1 Mar 24
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
28 Feb 24